Compare Amphastar Pharmaceuticals Inc (AMPH) vs H2O America (HTO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs H2O America — how do they compare? Amphastar Pharmaceuticals Inc trades at $20.39 (market cap $863.95M), while H2O America trades at $62.24 (market cap $2.56B). The key difference: H2O America is far larger — about 3× Amphastar Pharmaceuticals Inc's market cap, and H2O America pays a 2.87% dividend while Amphastar Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMPH | HTO | |
|---|---|---|
Market Cap | $863.95M | $2.56B |
Sector | Health | Technology |
52-Week High | $30.81 | $65.43 |
52-Week Low | $16.87 | $44.44 |
Enterprise Value | $1.26B | $4.35B |
Dividend Yield | — | 2.87% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $20.78, up 4.9% today, with a bullish technical signal supported by moving averages. The stock shows mixed earnings performance with Q2 2026 beating estimates but Q1 and Q4 2025 missing. Fundamentals remain solid with a 10.76% net margin and reasonable valuation at 12.02 P/E. Recent news highlights Q2 2026 results and strategic shift toward proprietary drugs.
Outlook is cautiously optimistic with growth supported by new product launches, though regulatory risks and earnings volatility pose challenges. Analyst sentiment is mixed with 25% buy ratings but majority hold recommendations. The stock offers value but requires monitoring of FDA developments and earnings consistency.
HTO trades at $62.66, up 1.42% with a bullish technical signal supported by moving averages. The company reported mixed earnings with Q2 2026 EPS beating expectations at $0.72 versus $0.699, but Q4 2025 missed. Fundamentals show strong gross margins at 56.91% and revenue growth to $829M projected for 2026. Recent news highlights institutional acquisitions and transformative Texas water utility expansion via the Quadvest deal.
Outlook remains positive with analyst consensus Buy rating (83%) and $69.50 price target offering ~11% upside. Key risks include execution challenges from acquisitions and EPS dilution from recent equity issuance. The dividend yield appears sustainable given cash flow trends, supporting income investors amid steady utility growth prospects.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About H2O America
H2O America is a utility company that provides essential water and wastewater services, primarily in the United States. The company operates a network of regulated water and wastewater systems, focusing on responsible resource management and high-quality service delivery. HTO aims to expand its operational footprint through acquisitions and internal growth, serving residential, commercial, and industrial customers.
Read more on HTO →
